参一胶囊联合卡培他滨治疗复发转移乳腺癌的临床观察

目的 探讨参一胶囊联合卡培他滨（CAP）治疗复发转移多耐药乳腺癌的疗效和毒副反应。 方法 选择我院2009年5月至2014年6月收治的晚期女性乳腺癌患者56例，按随机数字表法分为单药组（28例）：卡培他滨2 500 mg/m²，分2次口服，连服2周，1周后开始下一个周期；联合组（28例）：卡培他滨剂量、用法同单药组；参一胶囊每次2粒，2次/d，连续服用8周为1个周期，2个周期结束后进行疗效评估。结果 单药组有效率为39.3%，联合组有效率为50.0%，联合组有效率高于单药组，但差异无统计学意义（P>0.05）；两组患者白细胞减少、手足综合征、血小板下降等发生率比较差异无统计学意义（P>0.05）。结论 参一胶囊联合卡培他滨治疗复发转移性乳腺癌的疗效可能优于卡培他滨单药，值得进一步研究。

Efficacy and safety of ShenYi capsule combined with capecitabine as rescue therapy for advanced breast cancer

Objective To investigate the efficacy and side effects of ShenYi capsule combined with capecitabine （CAP） in the treatment of advanced breast cancer. Methods A total of 56 patients with advanced breast cancer treated in our hospital between May 2009 and June 2014 were randomly divided into two groups. The CAP group received oral CAP（1250 mg/m²） twice daily on days 1-14，and this cycle was repeated every four weeks. The Combination group received the CAP regime as in the CAP group，as well as two ShenYi capsules twice daily on an 8-week cycle. Efficacy was evaluated at the end of the second CAP cycle. Results The rate of complete+partial response was 39.3% in the CAP group and 50.0% in the Combination group，but this difference did not achieve signifi-cance （P>0.05）. The two groups did not differ significantly in the incidence of hand and foot syndrome or in platelet count decreases. Conclusion The combination of CAP and ShenYi capsule may be a more effective treatment for advanced breast cancer than CAP alone，and further clinical research is warranted.